Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2018

At a glance

  • Drugs CORT 125281 (Primary) ; Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 Nov 2017 According to a Corcept Therapeutics media release, the study has been initiated in healthy subjects. Dose ranging in combination with Xtandi (enzalutamide) in patients with castration-resistant prostate cancer is expected to start this quarter.
    • 02 Nov 2017 Status changed from planning to recruiting, according to a Corcept Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top